The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
BUSINESS
Astellas Looks to Fortify China Biz via Global Commercial Rejig
Astellas Pharma has implemented a revamp of its global commercial structure as part of its efforts to beef up its operations in the Chinese market, creating an independent sales unit for China, President and CEO Kenji Yasukawa revealed on April…
To read the full story
Related Article
- Astellas’ Net Profit Soars 35% on Xtandi, Betanis
April 26, 2019
BUSINESS
- Shionogi’s OIC Med Naldemedine Accepted for Review in China
June 2, 2025
- Astellas Nabs Rights to China Firm’s CLDN18.2 ADC
June 2, 2025
- Daiichi/Merck Pull HER3-DXd Filing for NSCLC in US
June 2, 2025
- Novo Pairs Up with Sumitomo on Ozempic Promotion in Japan
June 2, 2025
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…